Loss to Follow-up in PDR Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04018326|
Recruitment Status : Completed
First Posted : July 12, 2019
Last Update Posted : July 12, 2019
This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients' perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of anti-vascular endothelial growth factor (VEGF).
This prospective cohort study included 467 patients with PDR who received PRP and/or IVIs of anti-VEGF between May 2013 and June 2018. LTFU was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. Main outcome measures include rates and causes of LTFU.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||467 participants|
|Official Title:||Causes and Clinical Impact of Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy|
|Actual Study Start Date :||May 1, 2013|
|Actual Primary Completion Date :||June 1, 2018|
|Actual Study Completion Date :||December 25, 2018|
The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
Loss to follow-up (LTFU)
LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
- Final BCVA [ Time Frame: "through study completion, an average of 1 year", ]logMAR BCVA at final follow up (Snellen equivalent)
- Final UCVA [ Time Frame: "through study completion, an average of 1 year", ]Final logMAR UCVA (Snellen equivalent)